<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00035620</url>
  </required_header>
  <id_info>
    <org_study_id>990130</org_study_id>
    <nct_id>NCT00035620</nct_id>
  </id_info>
  <brief_title>Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy</brief_title>
  <official_title>A Study of Single Dose Per Cycle Filgrastim-SD/01 as an Adjunct to VAdriaC/IE Chemotherapy in Pediatric Sarcoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      Physicians are conducting a clinical trial for patients with pediatric sarcoma. Sarcoma is a
      type of bone cancer that can be treated with chemotherapy which can affect the bone marrow,
      where blood cells are produced. Neutrophils are a type of white blood cells that fight
      infection and are produced in the bone marrow. If the neutrophil count becomes too low due to
      chemotherapy, a potentially serious condition called neutropenia occurs. Neutropenia is
      serious because it can affect the body's ability to protect against many types of infections.
      Pegfilgrastim is an investigational drug being evaluated for its potential ability to
      increase the number of neutrophils. The purpose of this study is to determine the safety and
      effectiveness of pegfilgrastim in preventing neutropenia following chemotherapy in pediatric
      patients up through the age of 21 with sarcoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of severe neutropenia in chemotherapy in cycles 1 and 3</measure>
    <time_frame>cycles 1 and 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to ANC recovery to greater than or equal to 0.5 x 10^9/L in cycles 1 and 3</measure>
    <time_frame>cycles 1 and 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile in chemotherapy cycles 1 and 3</measure>
    <time_frame>cycles 1 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events across all cycles of chemotherapy</measure>
    <time_frame>all cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall rates of febrile neutropenia</measure>
    <time_frame>all cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Sarcoma</condition>
  <condition>Neutropenia</condition>
  <arm_group>
    <arm_group_label>Filgrastim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Filgrastim</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegfilgrastim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegfilgrastim</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>pegfilgrastim</description>
    <arm_group_label>Pegfilgrastim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>filgrastim</description>
    <arm_group_label>Filgrastim</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Sarcoma * No previous chemotherapy or radiotherapy * Patients who will be receiving
             chemotherapy consisting of Vincristine, Doxorubicin, Cyclophosphamide, Etoposide,
             Ifosfamide, and Mesna
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://www.neulasta.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2002</study_first_submitted>
  <study_first_submitted_qc>May 3, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2002</study_first_posted>
  <last_update_submitted>February 25, 2010</last_update_submitted>
  <last_update_submitted_qc>February 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Bone cancer</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

